China’s liver cancer screening market could reach US$7.2 billion in 2023, according to Frost and Sullivan. Photo: ShutterstockChina’s liver cancer screening market could reach US$7.2 billion in 2023, according to Frost and Sullivan. Photo: Shutterstock
China’s liver cancer screening market could reach US$7.2 billion in 2023, according to Frost and Sullivan. Photo: Shutterstock

China’s high hepatitis prevalence could be a boon for genomic tests developers for early screening of liver cancer

  • The country, a global hotspot for liver diseases, has emerged as an attractive target market for developers of genomic liver cancer screening tests
  • China accounts for a quarter of the world’s chronic hepatitis B infections and half the liver cancer-related cases

Topic |   Cancer
China’s liver cancer screening market could reach US$7.2 billion in 2023, according to Frost and Sullivan. Photo: ShutterstockChina’s liver cancer screening market could reach US$7.2 billion in 2023, according to Frost and Sullivan. Photo: Shutterstock
China’s liver cancer screening market could reach US$7.2 billion in 2023, according to Frost and Sullivan. Photo: Shutterstock
READ FULL ARTICLE